ReviewTechnology in cancer research & treatment2018
Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
Review in Technology in cancer research & treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review.BMC pulmonary medicine · 2019Pooled it
- Enhanced Detection of Druggable Mutations in Non-Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue.JCO precision oncology · 2025Article
- *Mechanisms of circular RNA in drug resistance of lung cancer: therapeutic targets, biomarkers, and future research directions.Discover oncology · 2025Review
- Application of Liquid Biopsy Technology in Lung Cancer: A Bibliometric Study and Visualization Analysis.Cancer management and research · 2025Review
- Recent Advances in Image-Guided Tissue Sampling.Cureus · 2024Review
- Observational
- Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.International journal of molecular sciences · 2023Review
- Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients.Biomarker research · 2022Article
- A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- Prognosis and Biological Function of miR-3195 in Non-Small Cell Lung Cancer.Cancer management and research · 2022Article
- Progress and application of circulating tumor cells in non-small cell lung cancer.Molecular therapy oncolytics · 2021Review
- Evaluation of microRNAs as potential biomarkers in circulating HPV-DNA-positive non-small cell lung cancer patients.Cancer biology & therapy · 2021Article
- PMEPA1 facilitates non-small cell lung cancer progression via activating the JNK signaling pathway.Cancer biomarkers : section A of Disease markers · 2021Article
- Silencing of BRF2 inhibits the growth and metastasis of lung cancer cells.Molecular medicine reports · 2020Article
- Liquid Biopsy is Instrumental for 3PM Dimensional Solutions in Cancer Management.Journal of clinical medicine · 2020Review
- Circulating tumor cells in the clinical cancer diagnosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.Cancer management and research · 2020Article
- Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.BMC medical genomics · 2019Article
- Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid.Frontiers in oncology · 2019Article
- The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The range of potential applications of liquid biopsies for non-small cell lung cancer management is expanded by the use of circulating tumor deoxyribonucleic acid and circulating tumor cells. Principal studies have demonstrated the predictive accuracy of droplet digital polymerase chain reaction detection, next-generation sequencing, and circulating tumor cells detection in patients with non-small cell lung cancer. The translational potential of these liquid biopsy technologies promotes the improvement of sensitivity and specificity in genomic and molecular methods. Here, we highlight the realities and challenges associated with the use of liquid biopsies for the detection of non-small cell lung cancer in patients. However, liquid biopsy technologies including circulating tumor cells detection, droplet digital polymerase chain reaction detection, and next-generation sequencing detection for precision therapy in non-small cell lung cancer will show substantive clinical applications in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.